Summit Therapeutics's total assets for Q3 2025 were £261.73M, a decrease of -19.23% from the previous quarter. SMMT total liabilities were £69.47M for the fiscal quarter, a 7.54% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.